Cargando…

Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients – a study based on a cohort of 19,742 patients

BACKGROUND: For a decade, patients have been advised against using high citalopram- and escitalopram-doses due to risk for ventricular arrhythmia and cardiac arrest. Still, these drugs are widely used to treat depression and anxiety especially in older patients. It is unclear why they are cardiotoxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Faraj, Pari, Størset, Elisabet, Hole, Kristine, Smith, Godfrey, Molden, Espen, Dietrichs, Erik Sveberg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474154/
https://www.ncbi.nlm.nih.gov/pubmed/37639937
http://dx.doi.org/10.1016/j.ebiom.2023.104779
_version_ 1785100429791592448
author Faraj, Pari
Størset, Elisabet
Hole, Kristine
Smith, Godfrey
Molden, Espen
Dietrichs, Erik Sveberg
author_facet Faraj, Pari
Størset, Elisabet
Hole, Kristine
Smith, Godfrey
Molden, Espen
Dietrichs, Erik Sveberg
author_sort Faraj, Pari
collection PubMed
description BACKGROUND: For a decade, patients have been advised against using high citalopram- and escitalopram-doses due to risk for ventricular arrhythmia and cardiac arrest. Still, these drugs are widely used to treat depression and anxiety especially in older patients. It is unclear why they are cardiotoxic and at what serum concentrations patients are at risk for arrhythmias. Thus, how many patients that are at risk for iatrogenic cardiac arrest is unknown. METHODS: We studied the arrhythmogenic effects of citalopram, escitalopram and their metabolites on human cardiomyocytes. Concentrations showing pro-arrhythmic activity were compared with observed drug and metabolite serum concentrations in a cohort of 19,742 patients (age 12–105 years) using escitalopram or citalopram in Norway (2010–2019). As arrhythmia-risk is related to maximum serum concentration, this was simulated for different age-groups from the escitalopram patient material. FINDINGS: Therapeutic concentrations of both citalopram and escitalopram but not their metabolites showed pro-arrhythmic changes in the human cardiac action potential. Due to age-dependent reduction of drug clearance, the proportion of patients above threshold for arrhythmia-risk increased with age. 20% of patients >65 years were predicted to reach potentially pro-arrhythmic concentrations, following intake of 10 mg escitalopram. INTERPRETATION: All patients that are using escitalopram or citalopram and have genetic disposition for acquired long-QT syndrome, are >65 years, are using additional pro-arrhythmic drugs or have predisposition for arrhythmias, should be monitored with therapeutic drug monitoring (TDM) to avoid exposure to potentially cardiotoxic concentrations. Serum concentrations should be kept below 100 nM, to reduce arrhythmia-risk. FUNDING: This study was funded by The Research Council of Norway (project number: 324062).
format Online
Article
Text
id pubmed-10474154
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104741542023-09-03 Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients – a study based on a cohort of 19,742 patients Faraj, Pari Størset, Elisabet Hole, Kristine Smith, Godfrey Molden, Espen Dietrichs, Erik Sveberg eBioMedicine Articles BACKGROUND: For a decade, patients have been advised against using high citalopram- and escitalopram-doses due to risk for ventricular arrhythmia and cardiac arrest. Still, these drugs are widely used to treat depression and anxiety especially in older patients. It is unclear why they are cardiotoxic and at what serum concentrations patients are at risk for arrhythmias. Thus, how many patients that are at risk for iatrogenic cardiac arrest is unknown. METHODS: We studied the arrhythmogenic effects of citalopram, escitalopram and their metabolites on human cardiomyocytes. Concentrations showing pro-arrhythmic activity were compared with observed drug and metabolite serum concentrations in a cohort of 19,742 patients (age 12–105 years) using escitalopram or citalopram in Norway (2010–2019). As arrhythmia-risk is related to maximum serum concentration, this was simulated for different age-groups from the escitalopram patient material. FINDINGS: Therapeutic concentrations of both citalopram and escitalopram but not their metabolites showed pro-arrhythmic changes in the human cardiac action potential. Due to age-dependent reduction of drug clearance, the proportion of patients above threshold for arrhythmia-risk increased with age. 20% of patients >65 years were predicted to reach potentially pro-arrhythmic concentrations, following intake of 10 mg escitalopram. INTERPRETATION: All patients that are using escitalopram or citalopram and have genetic disposition for acquired long-QT syndrome, are >65 years, are using additional pro-arrhythmic drugs or have predisposition for arrhythmias, should be monitored with therapeutic drug monitoring (TDM) to avoid exposure to potentially cardiotoxic concentrations. Serum concentrations should be kept below 100 nM, to reduce arrhythmia-risk. FUNDING: This study was funded by The Research Council of Norway (project number: 324062). Elsevier 2023-08-26 /pmc/articles/PMC10474154/ /pubmed/37639937 http://dx.doi.org/10.1016/j.ebiom.2023.104779 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Articles
Faraj, Pari
Størset, Elisabet
Hole, Kristine
Smith, Godfrey
Molden, Espen
Dietrichs, Erik Sveberg
Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients – a study based on a cohort of 19,742 patients
title Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients – a study based on a cohort of 19,742 patients
title_full Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients – a study based on a cohort of 19,742 patients
title_fullStr Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients – a study based on a cohort of 19,742 patients
title_full_unstemmed Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients – a study based on a cohort of 19,742 patients
title_short Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients – a study based on a cohort of 19,742 patients
title_sort pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients – a study based on a cohort of 19,742 patients
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474154/
https://www.ncbi.nlm.nih.gov/pubmed/37639937
http://dx.doi.org/10.1016/j.ebiom.2023.104779
work_keys_str_mv AT farajpari proarrhythmiceffectofescitalopramandcitalopramatserumconcentrationscommonlyobservedinolderpatientsastudybasedonacohortof19742patients
AT størsetelisabet proarrhythmiceffectofescitalopramandcitalopramatserumconcentrationscommonlyobservedinolderpatientsastudybasedonacohortof19742patients
AT holekristine proarrhythmiceffectofescitalopramandcitalopramatserumconcentrationscommonlyobservedinolderpatientsastudybasedonacohortof19742patients
AT smithgodfrey proarrhythmiceffectofescitalopramandcitalopramatserumconcentrationscommonlyobservedinolderpatientsastudybasedonacohortof19742patients
AT moldenespen proarrhythmiceffectofescitalopramandcitalopramatserumconcentrationscommonlyobservedinolderpatientsastudybasedonacohortof19742patients
AT dietrichseriksveberg proarrhythmiceffectofescitalopramandcitalopramatserumconcentrationscommonlyobservedinolderpatientsastudybasedonacohortof19742patients